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E-mail: jkota@iu.eduMicroRNAs (miRNA) are small non-coding RNAs (22 nt
in length) that are known as potent master regulators of eu-
karyotic gene expression. miRNAs have been shown to play a
critical role in cancer pathogenesis, and the misregulation of
miRNAs is a well-known feature of cancer. In recent years,
miR-29 has emerged as a critical miRNA in various cancers,
and it has been shown to regulate multiple oncogenic processes,
including epigenetics, proteostasis, metabolism, proliferation,
apoptosis, metastasis, fibrosis, angiogenesis, and immunomo-
dulation. Although miR-29 has been thoroughly documented
as a tumor suppressor in the majority of studies, some contro-
versy remains with conflicting reports of miR-29 as an onco-
gene. In this review, we provide a systematic overview of
miR-29’s functional role in various mechanisms of cancer
and introspection on the contradictory roles of miR-29.
MicroRNAs (miRNAs) are small non-coding RNAs, approximately
22 nt in length, that are known as powerful regulators of gene expres-
sion in eukaryotes. Since the first miRNA, lin-4, was reported in
1993,1 the field of miRNA biology has exploded in the past quarter
century, as revelations were made that these minute RNAs had colos-
sal implications in a multitude of physiological processes and dis-
eases. In the context of cancer pathogenesis, miR-15a/miR-16 was
the first miRNA cluster found to be aberrantly regulated, as their en-
coding genomic region was found to be deleted in chronic lympho-
cytic leukemia (CLL).2 Since then, dysregulated miRNA signatures
have become a well-established feature of various cancers. Among
dozens of miRNAs that have been reported to be abnormally ex-
pressed in cancer, miR-29 has been recognized as one of the critical
miRNAs that play a role in cancer pathogenesis.
miR-29 has been shown to have an important role in a multitude of
pathophysiological processes, ranging from cardiovascular3 to retinal
functions4 and even Alzheimer disease (AD).5 An increasing number
of in vivo and in vitro studies have demonstrated miR-29 to exhibit
strong anti-fibrotic activity by negative regulation of mRNAs encod-
ing extracellular matrix (ECM) proteins, such as collagen type I, alpha
1 and 2 (COL1A1, COL1A2), collagen type III alpha 1 (COL3A1),
elastin (ELN), and fibrillin 1 (FBN1), which play essential roles in
matrix deposition, epithelial-mesenchymal transition (EMT), and
the progression of fibrosis.6,7 Consistently, miR-29 is significantly
downregulated in human fibrotic disorders of multiple organs.
For example, in cardiac, pulmonary, hepatic, and renal fibroses,
miR-29 is found to be downregulated by transforming growth
factor b (TGF-b)-SMAD signaling, which in turn results in enhancedThis is an open access article under the CC BY-NC-expression of the collagen proteins, promoting pathogenesis of the
disease.7–12 In hepatic stellate cells (HSCs), key contributors of
collagen production and fibrogenic reactions in liver, miR-29 overex-
pressionmarkedly inhibits the increased expression ofHSC-activating
genes a-SMA, DDR2, FN1, ITGB1, and platelet-derived growth factor
receptor (PDGFR)-b in vitro.13 Taken together, deregulation of miR-
29 is associated with conditions such as myocardial fibrosis, cardiac
hypertrophy, congestive heart failure, chronic hepatic injury, hepatitis
C virus (HCV) infection and inflammation, hypertensive and diabetic
nephropathies, and chronic kidney diseases.3,12,14–18
In addition to fibrogenic disorders, miR-29 is reported to negatively
regulate insulin signaling via the inhibition of insulin receptor sub-
strate 1, phosphoinositide 3 kinase, and hexokinase 2, thereby playing
a pivotal role in glucose and fatty acid metabolism and type 2 dia-
betes.19,20 Furthermore, recent studies have delineated the role of
miR-29 in neurodegenerative diseases such as AD.21 In AD, patients
exhibit high levels of beta-secretase 1 (BACE1), an enzyme responsible
for b-amyloid peptide (Ab) formation from amyloid precursor pro-
tein gene (APP). Loss of miR-29 results in an associated increase in
BACE1 expression and Ab levels, promoting AD pathogenesis.5,21,22
In addition to the aforementioned diseases, a large body of literature
has demonstrated the significant role of miR-29 in various cancers.
The majority of these studies have reported that miR-29 functions
as a potent tumor suppressor gene, yet a few other reports have
also found oncogenic function of miR-29. To comprehensively sum-
marize the role of miR-29 in cancer, we have curated >150 primary
research articles pertaining to miR-29 spanning 13 different cancer
types. The search strategy was directed toward English language arti-
cles obtained through the PubMed electronic database to identify
peer-reviewed articles published and available to date. Here we offer
a systematic review synthesizing the current findings of miR-29 and
its roles in various mechanisms of cancer.miRNA Biology and the miR-29 Family
miRNAs are normally transcribed by RNA polymerase II and are
commonly embedded in the introns and exons of both coding andMolecular Therapy: Oncolytics Vol. 12 March 2019 ª 2018 173
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Schematic Representation of the miR-29 Family Members: miR-29a, -29b, and -29c
miR-29 family members have identical seed sequences (orange box and underlined) along with similar mature miRNA sequences. However, notable differences in
nucleotides are indicated in red. Tri-uracil nucleotides at positions 9–11 nt (blue box) present in miR-29b and -29c contribute to instability and shorter half-life, and the
hexanucleotide sequence at positions 18–23 nt (green box) is unique to miR-29b, leading to nuclear localization.
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istic hairpin structure and are referred to as primary miRNAs (pri-
miRNAs).23 Subsequently, pri-miRNAs are processed by ribonu-
clease enzyme Drosha in conjunction with a co-factor (DiGeorge
syndrome critical region in gene 8 [DGCR8] in humans or Pasha in
Drosophila melanogaster and Caenorhabditis elegans), forming the
microprocessor complex, which cleaves at the base of the hairpin.24,25
This liberated 60- to 70-nt hairpin structure is referred to as precursor
miRNA (pre-miRNA), which is exported out of the nucleus by the
RanGTP-dependent nuclear transport receptor exportin 526,27 and
further processed in the cytoplasm by an endonuclease RNase III
enzyme, Dicer, to yield an 22-nt long double-stranded mature
miRNA composed of a 5 prime (5p) and a 3 prime (3p)
strand.28,29 Finally, one of these strands of mature miRNA (passenger
strand) is degraded, while the other strand (guide strand or miRNA)
is loaded onto the Argonaut proteins (AGOs) to form the RNA-
induced silencing complex known as RISC.30,31 In the case of miR-
29, the miR-29-3p arm represents the most abundant and function-
ally relevant arm of all three family members.32,33 Following its
association within RISC, miRNAs function through a 6-8-mer
sequence, known as a seed sequence, that complementarily binds to
the 30 UTR of mRNA transcripts through canonical Watson-Crick
base pairing to regulate target expression.23,27 miRNA biogenesis is
a highly complex machinery, and we have provided a very simplified
overview of the entire process. A more detailed review of miRNA
biogenesis is available for further reading.25,27,29,31
Several miRNAs have common seed sequences and have been known
to largely regulate a similar repertoire of target transcripts. Accord-
ingly, evolutionarily conserved miRNAs sharing analogous seed se-
quences have been organized into 87 distinct miRNA families.34
One of these miRNA families, miR-29, consists of three members,
miR-29a, miR-29b, and miR-29c. miR-29a and -29b-1 are encoded
on human chromosome 7q32.3, known as the miR-29a/b-1 cluster,
and miR-29b-2 and -29c are found on chromosome 1q32.2, desig-
nated as the miR-29c/b-2 cluster. While all three family members
share a common 7-nt seed sequence, there are unique sequence-func-174 Molecular Therapy: Oncolytics Vol. 12 March 2019tional features of eachmiR-29 family member that have been reported
(Figure 1).
One of the notable differences amongmiR-29 family members resides
within a 6-nt segment that is unique to miR-29b (Figure 1). This hex-
anucleotide sequence present in nucleotide positions 18–23 has been
functionally shown to lead to miR-29b nuclear localization.35 In fact,
the simple addition of the miR-29b nuclear localization sequence
(NLS) to the 30 end of small interfering RNAs (siRNAs) was found
to be sufficient enough to cause nuclear localization.35 Consistently,
another report, evaluating the therapeutic efficacy of miR-29b in
targeting a subunit of the proteasome, found that the deletion of
the hexanucleotide NLS led to cytoplasmic enrichment of miR-29b
and further enhanced the downregulation of its target.36 Although
miR-29b’s function within the nucleus has yet to be fully elucidated,
this initial work has opened the gates to the discovery of various other
miRNAs that similarly localize to the nucleus and elicit non-canonical
gene regulation beyond binding to the 30 UTR ofmRNA transcripts in
the cytoplasm.37,38 The study of miRNA nuclear function is still active
and evolving. A number of reviews are available on this subject mat-
ter,39,40 but, for simplicity, we will focus on the canonical-cytoplasmic
function of miR-29 for the remainder of this review.
In addition,miR-29a has a distinct cytosine residue at position 10 (Fig-
ure 1). This difference is of particular importance, as uracil residues
located in nucleotide positions 9–11 of miRNAs have been found to
lead to rapid decay or turnover.41 This tri-uracil sequence is found
in both miR-29b and miR-29c, whereas the cytosine residue at nucle-
otide position 10 of miR-29a lends to its greater stability.41 This is
consistent with pulse-chase experiments of synthetic miR-29a and
-29b in HeLa cells demonstrating a longer half-life of miR-29a
compared to -29b,36 in addition to numerous findings demonstrating
that miR-29a is the most abundantly expressed family member.42–45
In Vivo Function of miR-29
A single miRNA family has been known to have, on average, >400
target transcripts that have matching, evolutionarily conserved
Figure 2. miR-29 Studies in Cancer Pathogenesis
A systematic curation of English language, primary research articles related to miR-29 in the context of cancer were comprehensively surveyed using the PubMed electronic
database in order to gain a better insight into the role of miR-29 in various cancers. (A) Bar graph indicating the number of existing publications based on cancer type, with
Miscellaneous (Misc) indicating studies that investigate miR-29 in a broader, multi-cancer context. (B) Pie chart with the numbers of publications demonstrating miR-29 as a
tumor suppressor (green), oncogenic (yellow), and having no effect (gray).
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human genome possess at least onemiRNA-binding site. Therefore, it
is not difficult to imagine that dysregulation of even a single miRNA
can profoundly impact normal physiological processes and lead to
disease.
In fact, a number of in vivo studies in murine models have demon-
strated the essential role of miR-29 in development and general
physiology. Whole-body miR-29 knockout (KO) mice have a wide
range of developmental defects, such as premature thymic involu-
tion,47 muscle wasting,48 growth retardation, and shorter lifespan.49
In addition, liver-specific miR-29 KO mice had a robust increase in
hepatic fibrosis and carcinogenesis,16 implicating its physiological
relevance.
A recent report profiled miR-29a and miR-29c function in the pan-
creata of whole-body KO mouse models in the context of glucose
regulation and diabetes.44 miR-29a KO mice had a defect in insulin
secretion, but, interestingly, miR-29c KO mice did not.44 Similarly,
miR-29a KO in an insulitis transgenic model (insHEL) resulted in
diabetes, whereas wild-type (WT) mice did not.44 Taken together,
miR-29a plays a vital role in proper pancreatic function and elicits
a protective effect against diabetes in the context of insulitis.44 miR-
29 clearly has a critical role in various organs in vivo to help main-
tain homeostasis and normal function, and its loss leads to develop-
mental problems and disease. Thus, it is not surprising that the
misregulation of miR-29 is reported in a variety of different cancer
types (Figure 2A) and that it predominantly functions as a tumor sup-
pressor (Figure 2B).Epigenetics
The genome is more than just the simple sequence of its nucleotides.
The term epigenetics was originally coined in 1942,50 where the
regulatory mechanism of gene expression was considered as a tran-
scending process to explain phenotype. Epigenetics is the study of
higher-order regulatory mechanisms influencing the expression of
genes without altering the underlying sequence. Since the original
conception of the term in 1942, the field of epigenetics has expanded
in the past several decades to include a multitude of molecular mech-
anisms (e.g., histone modifications, DNA methylation, miRNAs, and
long non-coding RNAs [lncRNAs]).
DNA methylation is a well-studied mechanism of epigenetic regula-
tion, and it has been shown to be aberrantly regulated in cancer.
Methylated DNA effectively silences genes through preventing the as-
sociation of activator proteins and recruiting methyl-CpG-binding
proteins (MBD) to deacetylate neighboring histones. DNA methyl-
ation of CpG islands is catalyzed by a class of proteins known as
DNA methyltransferases (DNMTs). Furthermore, DNMT family
members (DNMT1, DNMT3A, and DNMT3B) have been shown to
be elevated in a number of different cancers.51–54
As one of the earliest implications of miR-29’s role in epigenetic regu-
lation, all three miR-29 family members were found to act as tumor
suppressors in lung cancer through the direct targeting of a 30 UTR-
binding site on DNMT3A and DNMT3B transcripts.55 This was of
particular interest as DNMT3 was shown to be increased in lung
cancer and promote tumor growth by silencing various tumor sup-
pressor genes.51 Further in vivo studies demonstrated miR-29’s abilityMolecular Therapy: Oncolytics Vol. 12 March 2019 175
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Various other reports followed, corroborating the tumor-suppressive
role of miR-29 through targeting DNMT3s in other cancer contexts
(Table S1).
In addition to DNA methylation, the post-translational modification
of histones is another major epigenetic regulatory mechanism. Due to
the negatively charged phosphate backbone, DNA naturally associ-
ates with the positively charged lysine and arginine residues of histone
proteins, effectively packaging the DNA into units called nucleo-
somes.56 In the packed heterochromatic state, the DNA associated
with histones is effectively inaccessible, and promoter regions or
DNA elements within these regions are turned off. The acetylation
of lysine residues on the N-terminal tails of histones can neutralize
the positive charge of the side chain group, thus loosening its associ-
ation with DNA. This leaves the DNA more open to transcriptional
regulators. The reaction of acetylating lysine residues of histones is
facilitated by a class of enzymes called histone acetyltransferases
(HATs). Conversely, the removal of acetyl groups is carried out by
histone deacetylases (HDACs). HDACs have been shown to promote
oncogenic processes and are considered therapeutic targets in amulti-
tude of cancers.57,58 In fact, several clinical trials are ongoing in an
attempt to implement HDAC inhibitors (HDACi) in combination
with other therapeutic agents (ClinicalTrials.gov: NCT01543074
and NCT01486277).
In a study involving multiple myeloma, synthetic miR-29b mimics
were shown to effectively inhibit class II HDAC4 expression,59 and
the 30 UTR miR-29-binding site was validated through luciferase
reporter assay. Furthermore, miR-29b expression was inversely corre-
lated with HDAC4 expression in various cancer cell lines as well as in
patient samples.59 The study went on to demonstrate that miR-29b
overexpression caused increased acetylation of histone H4, increased
apoptosis, and reduced migratory potential of myeloma cells. Inter-
estingly, HDAC inhibition also led to the upregulation of miR-29b,
indicating a feedforward mechanism. Finally, the administration of
miR-29b mimics in combination with a pan-HDAC inhibitor, Vori-
nostat, led to a significant increase in survival and decreased tumor
volume in vivo.59
In addition to miR-29 targetingDNMT3 andHDAC4, Thymine DNA
glycosylase (TDG) and ten-eleven translocation 1 (TET1) have been
indicated as direct targets of miR-29. TDG and TET1 are known to
facilitate active demethylation of DNA, where TET1 initiates DNA
demethylation, through hydroxylating methylated cytosine,60,61 and
TDG subsequently excises the modified methyl group, effectively de-
methylating DNA.62
One of the first reports of miR-29 targeting TET1 and TDGwas in the
human lung adenocarcinoma cell line A549.63 The miR-29-binding
sites within the 30 UTR of TET1 and TDGwere validated via luciferase
reporter assay.63 Consistently, TET1 and TDG targeting by miR-29, in
the context of various cancers through bioinformatics analysis of data,
was identified with The Cancer Genome Atlas (TCGA) data.64 Using176 Molecular Therapy: Oncolytics Vol. 12 March 2019a statistical method to derive recurrence scores between miRNAs and
mRNAs in complement to target prediction, a database of high-con-
fidence miRNA pathway networks for multiple cancer types was
created (http://cancerminer.org). As a proof of concept for their anal-
ysis, the authors described a potential regulatory role of miR-29 in
the DNA demethylation pathway through targeting TET1 as well as
TDG.64
Interestingly, TET1 has been shown to act as a potent tumor suppres-
sor in various oncogenic contexts.65,66 A study in breast cancer cell
lines revealed miR-29b overexpression led to increased proliferation,
colony formation, and migration through inhibiting TET1 to regulate
ZEB2.67 In contrast, thorough analysis of TCGA datasets across a
number of cancer types revealed that miR-29a is generally downregu-
lated, and TET1 and TDG are typically upregulated.64 These seem-
ingly contradictory results led to the idea that miR-29’s role in
epigenetic regulation as a tumor suppressor versus oncogene may
be more subtle and context dependent. However, it is clear from
the given studies that TET1 and TDG are bona fide targets of miR-
29.More recent work in stem cell differentiation has shown consistent
results of miR-29 effectively targeting TET1 in embryonic stem cell
differentiation.68,69 Further work is needed to better understand these
paradoxical findings.
Proteostasis
As the cell is challenged with various environmental stresses, main-
taining a balance of protein biogenesis and degradation, called proteo-
stasis, is a vital process in preserving cellular homeostasis. The loss of
this balance can lead to dysfunction and cell death. Cancerous cells
undergo a constant barrage of environmental stresses, including hyp-
oxia and nutrient deprivation, while meeting the demands of onco-
genic growth. Therefore, proteostasis is critically important for the
survival of transformed cells, and it has been proposed as an appealing
therapeutic target. Therapeutic targeting of proteostasis in the context
of cancer have been covered in several reviews.70–73 The proteasome
and the process of macroautophagy are essential for protein clearance
and turnover, and, in recent years, miR-29 has emerged as a novel
regulator of proteostasis by targeting several genes that are pertinent
to proteasome and autophagy pathways.
The proteasome is a protein complex that hydrolyzes peptide bonds
of polyubiquitinated proteins.72 The ubiquitin proteasome pathway
(UPP) is vital for regulating protein half-life and degrading damaged
or misfolded proteins.72 In complement to the proteasome, macroau-
tophagy, herein referred to as autophagy, is a key cellular process that
degrades large macromolecules for the maintenance of cellular
homeostasis and survival under stress conditions.74 Autophagy is
the process in which cytosolic components are enveloped by dou-
ble-membrane vesicles, called autophagosomes, and trafficked to
the lysosome for degradation and recycling.75 Subsequently, the hy-
drolases of the lysosomal compartments degrade cytoplasmic cargo
and release the degraded components into the cytosol for reuse.75
Recent studies document that the upregulation of autophagy can
serve as a survival mechanism in various malignancies.76–87 As cancer
www.moleculartherapy.org
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proteasome inhibitors and small molecule inhibitors of autophagy
for cancer therapy is an active area of research.
The first indication of miR-29’s role in proteostasis was reported in
the context of chemosensitizing myeloma to bortezomib, a therapeu-
tic proteasome inhibitor.36 Initially, there was an aim to screen several
thousands of miRNAs differentially expressed in bortezomib-resis-
tant cells, and miR-29a, 29b-1, miR-29b-2, and miR-29c were all
identified as significantly downregulated miRNAs. Upon the inhibi-
tion of miR-29b and miR-29c using antagomirs, the viability of bor-
tezomib-treated myeloma cells was found to be increased. miRNA
target prediction algorithms revealed a potential target involved in
proteasome activation called PSME4 as a direct target of miR-29b.
Finally, utilizing transgenic xenograft murine models, miR-29b
replacement was shown to decrease tumor volume and increase over-
all survival. Although further studies have not investigated miR-29
suppression of PSME4 in the context of cancer, another recent report
found similar results in the context of cardiovascular disease, where
miR-29b overexpression led to a PSME4 decrease and increased
oxidative stress.88
In addition to the proteasome, miR-29 has been shown to play a sig-
nificant role in regulating autophagy. Initial studies in bovine cells
infected with virus revealed endogenous bovine miR-29 had an
anti-viral protective effect of the host cell by upregulating miR-29b,
which led to the targeting of ATG14 and ATG9A. Bovine diarrhea
virus (BVDV) utilized host cell autophagy machinery as a means of
promoting viral replication. miR-29b-mediated inhibition of auto-
phagy led to a decrease in BVDV replication.89
Shortly thereafter, miR-29a was shown to have a similar effect inhib-
iting autophagy in pancreatic cancer cells. Earlier work demonstrated
that pancreatic cancer cells heavily upregulated autophagy for sur-
vival and that this upregulation also conferred chemoresistance
against a nucleoside analog, gemcitabine.87 miR-29a was significantly
downregulated in pancreatic cancer cells, and miR-29a overexpres-
sion led to increased gemcitabine sensitization in chemoresistant
cell lines. Subsequently, miR-29 overexpression led to a late-stage
blockage of autophagy, where co-localization of GFP-labeled auto-
phagosomes and lysosomal markers indicated a blockage in autopha-
gosome-lysosome fusion. By utilizing miRNA predictive algorithms,
two predicted autophagy-related miR-29 targets were identified,
TFEB and ATG9A. TFEB and ATG9A are known to be vital for lyso-
somal function and autophagosome trafficking, respectively, and they
are indispensable for autophagy. Indeed, miR-29 overexpression led
to a drastic decrease in expression of both targets. Parallel knockdown
of TFEB and ATG9A phenocopied the late-stage blockage of auto-
phagy similar to miR-29 overexpression, but, interestingly, only the
knockdown of ATG9A demonstrated a reduction in autophago-
some-lysosome fusion.
While initial findings of miR-29b targeting bovine ATG9A were
originally reported, we found consistent regulation in human carci-noma. Furthermore, in a study involving the silencing of HDAC4
by miR-29b in multiple myeloma, miR-29 overexpression led to a
decrease in TFEB.59 Although postulated that this was an indirect
effect of repression through the knockdown of HDAC4, it may
be possible they were, in fact, observing a direct targeting of
TFEB by miR-29b. However, in subsequent studies, overexpression
of miR-29a in myeloma cells had no impact on autophagy flux.59
These results may indicate that miR-29-mediated autophagy inhi-
bition may be context dependent or differ between miR-29a and
-29b family members. Further investigation is warranted to deter-
mine if miR-29 has an impact on proteasome function in pancre-
atic cancer.
Oncogenic Metabolism
miR-29 has been implicated in regulating metabolism in numerous
tissue types, including b cells, skeletal muscle, and adipocytes,20,90,91
and it has been shown to regulate branch-chain amino acid synthesis
and insulin secretion.91,92 Therefore, it is not surprising that miR-29 is
also found to have an impact on cancer metabolism. The area of can-
cer metabolism has been well studied over the past several decades,
and many alterations in metabolic processes, including glycolysis,
oxidative phosphorylation, and mitochondrial function, have been
discovered as a compensatory mechanism of cancer cells to meet
the energy demands of oncogenesis.
One of the first studies elucidating the role of miR-29 in cancer meta-
bolism found the downregulation of miR-29b in ovarian cancer, and
its restoration led to an inhibition of glycolysis and glucose meta-
bolism in cancer cells by directly targeting AKT2 and AKT3.93
AKT, also known as protein kinase B, is a key hub within the PI3K/
AKT/mTOR-signaling pathway. Furthermore, AKT is well known
to be activated in tumors and regulates glucose metabolism to
promote cancer growth.94,95 The 30 UTR miR-29-binding sites of
AKT2/3 were validated, and miR-29b overexpression led to decreased
tumor formation in vivo.93 Although outside of the metabolism
context, various other groups have demonstrated a similar tumor-
suppressive function of miR-29 by targeting AKT (Table S1), thus
reassuring that AKT is a bona fide target of miR-29.
In addition to facilitating a tumor-suppressive function through regu-
lating glucose metabolism, miR-29 has also been shown to be concert-
edly regulated in the context of lipid metabolism, and it functions as a
tumor suppressor in glioblastoma multiforme (GBM) through an
autoregulatory loop involving Sterol regulatory element-binding pro-
tein 1 (SREBP-1).96 SREBP-1 is a transcription factor that concertedly
regulates genes involved in sterol biosynthesis and glucose and lipid
metabolism,97 and it has been known to promote tumorigenesis.98
SREBP-1 was found to suppress miR-29 expression at both loci
(miR-29a/b-1 and miR-29c/b-2), and deletion of sterol regulatory
element (SRE)-binding sites in the promoters of miR-29 loci dere-
pressed miR-29 expression.96 Interestingly, SREBP1 itself was shown
to be a direct target transcript of miR-29, and, ultimately, miR-29
forced expression in GBM led to a significantly increased survival
and decreased tumor growth in vivo.Molecular Therapy: Oncolytics Vol. 12 March 2019 177
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and ATPIF1, two vital subunits of ATP synthase.99 The overexpres-
sion of miR-29a/b-1 caused tamoxifen sensitization in tamoxifen-
resistant cells.99 Gene ontology analysis of the miR-29a transcriptome
in ovarian cancer cells revealed various differentially expressed genes
(DEGs) related to oxidative phosphorylation and ATP metabolism.99
Further investigations revealed miR-29a overexpression led to a
decreased oxygen consumption rate, mediated by the direct inhibition
of ATP5G1 and ATPIF1 expression.99 Although these findings neces-
sitate further in vivo verification, they convey additional evidence of
miR-29’s tumor-suppressive role in regulating cancer metabolism.
Proliferation
Uncontrolled proliferation is a hallmark of cancer cells, and several
cell cycle regulators are well known to be dysregulated in tumors.
Understanding the molecular details of cell cycle regulation and
checkpoint abnormalities in cancer have been under intense investi-
gation for the past several years. The targeting of cell cycle control
mechanisms has risen as a promising therapeutic strategy.100
Themain regulatory proteins that play key roles in controlling cell-cy-
cle progression include cyclins, cyclin-dependent kinases (CDKs), and
various cyclin substrates.101 CDK6 plays an important role in the tran-
sition of cycling cells into S phase. Studies have reported that cyclin-
CDK6 complexes induce cancer cell transition from G1 to S phase
by phosphorylation of retinoblastoma (Rb), while CDK6 inhibition
blocks the cell cycle and suppresses tumor growth.102,103 In fact, several
CDK6 inhibitors have been developed to target proliferating cancer
cells.104CDK6 has been shown to be a direct target ofmiR-29 in several
malignancies, including mantle cell lymphoma,105 acute myeloid
leukemia (AML),106 and cervical cancer.107 For example, CDK6 was
shown to be directly targeted by miR-29 in melanoma cell lines. In
various melanoma cell lines, miR-29a/b expression inversely corre-
lated to cancer cell proliferation. Previous work had demonstrated
an anti-proliferative effect of interferon (IFN)-g in many cancers.108
Accordingly, IFN-g as well as miR-29 exhibit anti-proliferative activ-
ities in melanoma cells involving downregulation of CDK6.109 Consis-
tently, miR-29 was shown to be involved in Burkitt lymphoma patho-
genesis by altering the expression of target genes, including CDK6,
DNMT3B, TCL1, andMCL1, which are involved in cell cycle control,
DNA methylation, and apoptosis inhibition, respectively.110 More-
over, miR-29 has also been observed to enrich the E7 protein-depen-
dent cell cycle pathway by targeting CDK6, resulting in decreased
proliferation of cervical cancer cells.111 Furthermore, cell cycle analysis
revealed thatmiR-29 overexpression caused a significant accumulation
of cervical cancer cells at the G1 phase and decreased the number of
cells in the S and G2/M phases.112 In schwannoma, miR-29a has
been shown to downregulate CDK6 expression and disrupt cell cycle
progression by the deactivation of JNK and p38MAPK/ERKpathways.
Overexpression of all three members of the miR-29 family in Schwann
cells inhibited cell viability, migration, and invasion in vitro.113
Interestingly, a recent study identified a novel oncogenic circular
RNA, circRNA_100290, which contained two miR-29-binding sites178 Molecular Therapy: Oncolytics Vol. 12 March 2019that acted as a sponge to sequester miR-29 family members in oral
squamous cell carcinoma (OSCC).114 The inhibition of miR-29b
led to the upregulation of CDK6 expression. Knockdown of
circRNA_100290 was found to induce G1/S arrest and inhibit
in vitro and in vivo OSCC cell proliferation and reduce CDK6
expression.
AnothermiR-29 target, cell division cycle 42 (CDC42), is awell-known
member of the Ras homolog (Rho) family, and it regulates crucial
cellular processes, including cell cycle and cell cytoskeleton organiza-
tion.115,116 miR-29a was shown to exert a tumor suppressor role in
breast cancer cells by arresting the cell cycle at the G0/G1 phase
through the negative regulation of CDC42 expression.117 In corrobo-
ration with this study, miR-29 was found to be downregulated in
clear cell renal cell carcinoma, and restoration of all three miR-29
family members inhibited cell proliferation along with migration-
invasion.117
As covered in the Oncogenic Metabolism section, the AKT kinase
family is well known for its role in promoting tumorigenesis. One
mechanism by which AKT functions as an oncogene is through pro-
moting cell proliferation by accelerating G2-M phase transition.118
miR-29 has been shown to inhibit myoblast proliferation by targeting
AKT3 as well as another proliferation-associated gene, p85a. siRNA-
mediated AKT3 knockdown in the C2C12 myoblast cell line was
shown to phenocopy miR-29 overexpression, leading to cell-cycle
arrest in the G0/G1 stage and a significant decrease in proliferation
rate.119 In addition toAKT3,AKT2 and CCND2 have also been shown
to be direct targets of miR-29. AKT2 functions as the hub in the PI3K/
AKT-signaling pathway,120–122 and CCND2 is a member of the cy-
clins, promoting the G1-to-S phase transition through regulating
the phosphorylation of Rb.123,124 The role of miR-29 in significantly
inhibiting AML cell proliferation and promotion of apoptosis was
attributed to the decrease of these two key signaling molecules.125
Furthermore, in vivo analysis demonstrated that the reintroduction
of each miR-29 member could partially correct abnormal cell prolif-
eration and apoptosis repression and mediate myeloid differentiation
arrest in AML.125
In addition to CCND2, miR-29 also targets E2F7, as demonstrated in
Rhabdomyosarcoma (RMS). E2F7 is essential for cell survival and
embryonic development in mice. Furthermore, ectopic expression
of E2F7 has been shown to block cell cycle transition, resulting in
G1 arrest.126,127 CCND2 and E2F7 were upregulated in both RMS
types, and miR-29 expression was shown to be inversely correlated
to these cell cycle genes, suggesting that miR-29 may function as a
tumor suppressor in RMS by targeting CCND2 and E2F7. Ultimately,
overexpression of miR-29 downregulated the expression of these cell
cycle genes and induced partial G1 arrest, leading to decreased cell
proliferation.128
Finally, miR-29 also targets FOXM1. FOXM1 is a conservative tran-
scription factor that can mediate cell growth, proliferation, and
apoptosis through regulating gene expression.129A studydemonstrated
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growth and proliferation and promoted apoptosis by downregulating
FOXM1 expression level.
Apoptosis
The apoptotic pathway is an important pathway in all stages of tumor
development and metastasis. Apoptosis is a naturally acquired pro-
cess that typically plays an important role in the development and
life of multicellular organisms, by removal of damaged, aged, or auto-
immune cells through a controlled cell death mechanism.130
Apoptosis involves a fine-tuned regulatory mechanism, as it is
categorized as a type I form of programmed cell death; therefore,
the mechanism of apoptosis is complex and involves numerous
signaling pathways. Critical changes may occur at any point along
these pathways, leading to tumorigenesis, metastasis, and resistance
to anticancer drugs.131,132 A large body of experimental evidence doc-
uments that miRNAs function as important regulators of cancer cell
death. In an effort to re-establish miRNAs function in apoptotic path-
ways, many strategies have been designed to either block the expres-
sion of oncomiRs or to boost the expression of tumor suppressor
miRNAs.133
miR-29a and -29b have been shown to regulate critical anti-apoptotic
genes such as MCL1. MCL1, part of the BCL family, is an anti-
apoptotic protein that promotes cancer cell survival and proliferation,
and it is frequently overexpressed in cancer, notably in AML.134–137
miR-29b has been shown to be deregulated in primary AML blasts,
and transcriptome analysis after miR-29b overexpression in leukemia
cells revealed a tumor suppressor function, in which miR-29 induced
apoptosis through directly targeting MCL1, as indicated by Annexin
V/propidium iodide (PI) assay and increased caspase activity.138
These results of miR-29b targetingMCL1 to elicit a tumor suppressor
effect were consistent in vivo.138 In addition, an inverse relationship of
miR-29 and MCL-1 expression in the transformation of myelodys-
plastic syndromes (MDS) to overt leukemia (OL) was observed.138
Furthermore, miR-29a has been shown to have anti-invasive and
anti-proliferative effects on lung cancer cells in vitro, which can be
explained in part by the ability of the miR-29 family to downregulate
Mcl-1 activity and target RAN, a member of the RAS oncogene
family.139
miR-29 also regulates environmental signals like growth factors that
have an extrinsic impact on cell cycle control. It was found that the
knockdown of miR-29 inhibited proliferation and induced apoptosis
in MG-63 osteosarcoma cells by TGF-b1/PUMA signaling. PUMA is
a BH3-only member of the Bcl-2 family and a target of p53-mediated
apoptosis.140 It activates an apoptotic cascade by facilitating Bax
activation, causing cytochrome c release from the mitochondria, cas-
pase-3 activation, and DNA fragmentation.141,142 It was also found
that miR-29 could target pro-apoptotic PUMA protein and protect
against ischemia-reperfusion injury, suggesting that PUMA might
be negatively regulated by miR-29. Some studies have reported that
PUMA was a direct TGF-b target gene in B cells and that TGF-b in-
duces PUMA to aid induction of the intrinsic cell death pathway.143Furthermore, this study also demonstrated the tumor suppressor
effect of miR-29 in vivo.144
miR-29 also affects proliferation through epigenetic control. miR-29
was identified as a negative regulator of SETDB1, thereby reducing
hepatocellular carcinoma (HCC) cell proliferation in vitro and
suppressing orthotopic tumorigenicity in vivo. Downregulation of
miR-29 expression in human HCC contributed to SETDB1 upregula-
tion by relieving its post-transcriptional regulation. The biological
reasons behind this global upregulation of epigenetic regulators in
human HCC remain to be elucidated. One possible explanation is
that cancer cells are actively dividing and undergoing more dynamic
epigenetic reprogramming during cell cycles, and, therefore, they
may require increasing amounts of epigenetic regulators to sustain
their continuous growth and clonal evolution.145 From these studies,
it is becoming clear that the miR-29 family plays an anti-apoptotic
role in several cancers by targeting key regulators in apoptotic
pathways.
Metastasis and EMT
Metastasis occurs when cancer cells undergo EMT, a cellular reprog-
ramming event in which epithelial cells revert to a pseudo-stem cell
state that is characterized by a loss of polarity and increased migratory
behavior.146 EMT plays a vital role in normal physiology during
development as well as in wound healing, but it is also exhibited in
cancer metastasis, where a subset of tumor cells disseminates to
distant organ sites beyond the site of origination. As a defining signa-
ture of stage IV cancer, metastasis is regarded as a major cause of
cancer mortality.147 This is largely because, by the time cancer has
metastasized, surgical resection is typically no longer a viable option
and metastatic tumors are often refractory to conventional therapies.
miR-29 has been implicated to inhibit a number of genes that are
involved in EMT andmetastasis, even causing the reversion ofmesen-
chymal-epithelial transition (MET) in some cases. However, in
contradiction, miR-29 itself has also been shown to directly elicit
EMT in a minority of cases.
An initial study in gastric cancers revealed d-catenin (CTNND1) as a
target of miR-29.148 d-catenin plays an important role in cell adhesion
between cells and mediates metastatic signal transduction. Mislocali-
zation of d-catenin in the cytoplasm or nucleus resulted in the
advancement of migration and invasion via regulating Rho GTPase
activity and growth factor receptor signaling, implying CTNND1’s
role as an oncogene.149,150 A follow-up study in gastric cancer found
that the loss of miR-29 contributed to chemoresistance, and overex-
pression of all three miR-29 family members directly inhibited
CTNND1, leading to an increased F-actin andCofilin phosphorylation
via activated RhoA.151 As the F-actin/RhoA pathway is known to in-
fluence cell migration, in vitro migration assays demonstrated that
miR-29c potently inhibited the migratory potential of gastric cancer
cells. Consistently, miR-29c inhibited gastric cancer cell metastasis
in vivo as well.151 These results confirm that miR-29 controls gastric
cancer cell movement by suppressing the catenin-d pathway.
Similarly, another group also reported that miR-29c/b-2 delivery viaMolecular Therapy: Oncolytics Vol. 12 March 2019 179
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and migration in vitro.152
Dysregulation of miR-29 s also affects cancer cell invasion and
migration by the activation of several oncogenic pathways, such
as the Wnt/b-catenin pathway. For example, miR-29a overexpres-
sion led to decreased b-catenin expression and cell proliferation
in non-small-cell lung cancer (NSCLC).153 miR-29b was shown to
inhibit both Wnt/b-catenin and AKT signaling by downregulating
SPIN1 in triple-negative breast cancer (TNBC), and miR-29b over-
expression decreased in vitro TNBC cell growth, self-renewal,
migration, and invasiveness by inhibiting the aforementioned path-
ways.154 On the other hand, miR-29 has also been shown as a novel
target of b-catenin/Dicer. b-catenin represses Dicer, a key compo-
nent of the miRNA-processing machinery. Silencing of b-catenin
or overexpressing Dicer or miR-29 mimics in highly metastatic
ovarian cancer led to significantly reduced migration of cancer cells
in vitro.155
A similar anti-metastatic role of miR-29 has been found in HCC,
where miR-29a overexpression in HepG2 cells resulted in a significant
decrease in migration in vitro. Prior reports have implicated a role for
insulin-like growth factor (IGF) and type 1 IGF receptor (IGF-1R) in
metastasis.156 The study went on to validate miR-29a’s direct repres-
sion of IGF-1R expression.157 Taken together, miR-29a-mediated
inhibition of IGF1R exhibited a dual tumor suppressor role in HCC
by suppressing HCC cell migration while simultaneously increasing
CD8+ T lymphocyte migration.157 This secondary role of increasing
immune cell migration is further covered in the Immunomodulation
section.
It is important to note that, in addition to internal reprogramming
from EMT, the tumor microenvironment can promote and facilitate
metastasis. Different cancers tend to spread to specific organ sites,
lending to the seed and soil hypothesis of metastatic microenviron-
ments. Overexpression of ECM components, the major stromal pro-
teins in cancer, is observed in several tumor types, and it contributes
to cancer cell progression by the dysregulation of cell adhesion, polar-
ity, and structural remodeling through ECM-modifying enzymes.
miR-29 has been extensively shown to target integrin beta-1
(ITGB1).158 ITGB1 is part of the integrin family of cell surface recep-
tors that have been well established to promote cell growth, migra-
tion, and tumor metastasis in a majority of cancers.159 Integrins
typically heterodimerize in alpha/beta pairs and attach to ECM
proteins, which serve as tracks for chemotaxis.160 All three miR-29
family members have been shown to act as potent tumor suppressors
in several cancer cell lines, by directly inhibiting ITGB1 and, thereby,
inhibiting migration and invasion (Table S1).
The lysyl oxidase (LOX) protein family functions in covalent cross-
linking of collagen and/or elastin in the ECM. Dysregulation of
LOXL2 has been reported to correlate with disease progression in
several diseases and cancers. Furthermore, LOXL2 interacts with180 Molecular Therapy: Oncolytics Vol. 12 March 2019SNAIL1 transcription factor and represses E-cadherin along with
inducing EMT. miR-29 has been shown to have a tumor-suppressive
role by negatively regulating LOXL2 expression and inhibiting cancer
cell migration and invasion in renal cell carcinoma in vitro.117 More-
over, LOXL2 was shown to enhance cancer cell invasion in vitro and
promote the tumor microenvironment and metastatic niche forma-
tion in HCC, where it is activated by HIF-1a/SMAD4 and negatively
regulated by miR-26 and miR-29.161
Metallomatrix protease 2 (MMP2) is another ECM-modifying
enzyme that has been shown to promote metastasis and was found
to be a direct target of miR-29. MMP2 plays a critical role in cancer
metastasis, and the effects of MMPs on the ECM are well estab-
lished.159 Moreover, MMP2 is overexpressed in a variety of primary
malignancies, and it is considered an appealing therapeutic target.162
miR-29c has been shown to target MMP2 expression, causing
decreased pancreatic cancer cell invasion and metastasis in vitro
and in an orthotopic implantation model in nude mice. Moreover,
miR-29 expression was also found to inversely correlate with
MMP2 expression, metastasis, and survival in pancreatic cancer pa-
tients.163 Additionally, the other members of the miR-29 family
also regulateMMP2 expression.164 Similarly, miR-29b suppresses in-
vasion and metastasis by downregulating MMP2 in HCC, OSCC, and
colorectal cancer (CRC) (Table S1).
Similar to the previous reports on miR-29c, miR-29a overexpression
was also found to inhibit migration/invasion in pancreatic cancer cell
lines,165,166 but through different mechanisms. One study found that
miR-29a inhibited metastatic potential through targeting membrane-
bound mucin (MUC1).166 MUC1 is an epithelial marker of polarized
epithelial cells,167,168 but aberrant overexpression of MUC1 in cancer
cells is correlated with an induction of EMT through the Wnt/b-cat-
enin-signaling pathway.169 miR-29a was shown to directly inhibit
MUC1 expression, thereby deregulating signaling pathways promot-
ing EMT.166 Further studies on the anti-metastatic effects of miR-29
have been linked to its direct inhibition of genes encoding ECM
proteins. These related targets are covered more extensively in the
following Fibrosis/ECM section.
Finally, GATA3 is a well-studied transcription factor to have potent
tumor-suppressive function in various cancers, and it is known to
counteract metastasis by inducing MET.170 In breast cancer cells,
GATA3 mediated its tumor-suppressive role through the upregula-
tion of miR-29b.171 Through an extensive series of experiments, the
impact of miR-29b in breast cancer was thoroughly examined, and
it revealed that miR-29b inhibition led to a drastic decrease in various
epithelial markers, along with increases in mesenchymal markers.171
Furthermore, miR-29 inhibition in vivo resulted in a significant in-
crease in lung metastasis.171 Most impressively, the study went on
to show that miR-29 potently inhibited 15 different targets, including
Angiopoietin-like proteins, integrins, LOXL2, MMP, PDGF, TGFB,
and vascular endothelial growth factor A (VEGFA), which are all
known to influence metastasis and promote tumor microenviron-
ment progression.171 In summation, miR-29 functions epistatically
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cancer.
In contrast to a large body of experimental evidence lending to the
anti-metastatic function of miR-29, aberrant expression of the miR-
29 family has been reported to induce migration/invasion in certain
malignant contexts as well. In pancreatic cancer, miR-29a was re-
ported to act as an oncogene by downregulating tristetraprolin
(TTP), whose activity is known to be regulated by phosphorylation
through the p38 MAPK and ERK-MAPK pathways. Downregulation
of TTP increased the expression of pro-inflammatory factors and
EMT markers,172 and restoration of TTP decreased cell viability
and migration in vitro while inhibiting tumor growth and EMT
phenotype in vivo.172 Furthermore, miR-29 was also shown to nega-
tively regulate EMT regulator N-myc interactor (NMI) in breast can-
cer. Increased levels of miR-29 in breast cancer cells inhibited NMI
expression, leading to increased cancer cell invasion and promotion
of the EMT phenotype.173 With the absence of NMI, inactivation of
GSK3b leads to miR-29 upregulation through unrestricted Wnt/
b-catenin signaling.173 Moreover, in breast cancer, progestin-regu-
lated miR-29 can control progesterone receptor (PR) action by target-
ing progestin-responsive genes such as ATP1B1 as well as controlling
PGR expression itself.174 Downregulation of miR-29 relieves the
repression of ATP1B1, allowing it to adjust the progestin response.174
ATP1B1 limited cell motility, and knockdown of ATP1B1 led to
increased breast cancer cell migration and invasion in vitro.174
It is perplexing that miR-29 can have such stark contrasting effects on
metastasis reported within the same cancer types. These confounding
incongruities warrant further studies to better understand these
seemingly contradictory results.
Fibrosis/ECM
The ECM is a vital structure that has a dynamic and complex organi-
zation, and it can trigger multiple biological activities that are essen-
tial for normal organ development and tissue homeostasis. In mam-
mals, the ECM is composed of about 300 proteins known as the core
matrisome, which comprises proteins such as collagens; proteogly-
cans; and glycoproteins such as laminin, elastin, and fibronectin.
Dysregulated ECM remodeling leads to many diseases, namely,
fibrosis, which also increases the risk of cancer. Fibrosis is a complex
process that involves excessive deposition and reorganization of the
ECM, leading to EMT.175 Primarily, fibrosis is mediated by cancer
cells that activate fibroblasts, where activated fibroblasts then further
perpetuate sustained activation of themselves and other neighboring
fibroblasts175 and lead to fibrotic stromal reaction. Stroma is known
to impair drug delivery to the tumor core, promoting tumor progres-
sion and metastasis. Consequently, many targeted therapies sought to
completely ablate the stroma. However, increasing evidence suggests
a greater level of complexity to the story, as the stroma was shown to
restrain tumor growth in preclinical studies.176,177 Recent work has
demonstrated that the reductionist approach of all or nothing may
not be the appropriate means of targeting the stroma, rather a
more subtle degree of crosslinking and stromal density may be keyto having a therapeutic impact.178 With the failure of current
stroma-depleting therapeutic strategies, efforts are now focused on
developing novel stroma-targeted therapies that appropriately con-
trol the fibrotic stroma.
PDGFs and TGF-b are known to induce fibrosis by causing the
proliferation of fibroblasts that differentiate into myofibroblasts and
produce fibrotic ECM proteins. TGF-b1 is a well-known proinflam-
matory growth factor that is associated with the pathogenesis of
several cancers. TGF-b1 binds to TGF-b receptors (type I and type
II) to form an activated hetero-tetramer with serine-threonine kinase
activity, which phosphorylates downstream transcription factors
SMAD2 and SMAD3. Upon phosphorylation and activation,
pSMAD2/3 form a heterogeneous complex with SMAD4, translocate
into the nucleus, and directly regulate target gene expression. Several
of these target genes include ECM proteins, such as COL1A1,
COL3A1, and TIMP1, as well as about 60 other ECM-related genes.
Several studies have implicated that miRNAs function as potent reg-
ulators of the ECM, and, in particular, the miR-29 family has been
well established as a potent anti-fibrotic miRNA. Initial studies found
that miR-29 restoration quelled fibrosis and ECM protein production
in the context of numerous organs, including cardiac,6 liver,179 lung,10
and kidney180 fibroses. Moreover, TGF-b signaling is responsible for
the decreased miR-29 expression during fibrosis. Hence, targeting the
miR-29 family and TGF-b may be an effective strategy for the treat-
ment and management of fibrosis.181,182 The interaction between the
miR-29 family and TGF-b was revealed in lung and cardiac fibro-
ses.6,8 After treatment of TGF-b1 on miR-29 knockdown IMR-90
cells,8 certain genes were confirmed to be upregulated by TGF-b,
and these genes mainly consisted of miR-29-predicted targets, such
as collagens. Furthermore, the stimulation of TGF-b1 and knock-
down of miR-29 exhibited similar behavior in lung cells, and they
led to the upregulation of specific fibrotic genes, such as COL1A1,
COL3A1, and COL1A2. Various laminins, integrins, MMPs, and
ADAMs are upregulated with miR-29 downregulation as well, but
not with TGF-b1 stimulation.8 Therefore, these observations show
that the miR-29 family regulates gene expression via TGF-b-depen-
dent and -independent signaling pathways.
More recent studies revealed howmiR-29mediates TGF-b1 pathways
by targeting a variety of ECM network genes. For example, Hsp47, a
collagen-binding protein and collagen-specific chaperone, is a hub of
the ECM network and controls the tumor microenvironment by the
deposition regulation of several ECM proteins. A transcription
network analysis showed that Hsp47 expression was activated during
breast cancer development and progression, while Hsp47 silencing
reprogrammed human breast cancer cells to form growth-arrested
and/or non-invasive structures in 3D cultures, and, moreover, it
restricted tumor growth in xenograft assays by decreasing the depo-
sition of collagen (COL1A1 and COL4A1) and fibronectin (FN1).
Co-expression network analysis showed miR-29b and -29c were
inversely correlated with Hsp47 expression and other ECM network
genes. In summary, in an in vitro and in vivo breast cancer study,Molecular Therapy: Oncolytics Vol. 12 March 2019 181
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breast cancer by increased ECM deposition.183 An interesting study
found that knockdown of miR-29 enhanced the ionizing radiation-
induced expression of type I collagen through the TGF-b-Smad3-
signaling pathway in irradiated cells. Inhibition of TGF-b-Smad3
signaling blocked the significant loss of miR-29, and miR-29 overex-
pression inhibited the ionizing radiation-induced expression of type I
collagen, suggesting that miR-29 may be an important regulator of
radiation-induced fibrosis (RIF).184 However, further studies are
required to dissect the role of miR-29 in molecular mechanisms asso-
ciated with radiation.
Moreover, miR-29 downregulation leads to increased ECM protein
expression levels of collagens and laminins, as observed in a number
of cancers. Based on miRNA-mRNA covariation and sequence-based
target predictions, miR-29a/c were identified as novel regulators of
LAMA2, an ECM protein associated with poor prognosis in posterior
fossa (PF) ependymoma. Decreased miR-29a/c expression correlated
with elevated LAMA2 expression are features of PF ependymoma
post-transcriptional regulation.185 Moreover, the miR-29 family was
identified to have one of the strongest interactions between DEGs
in an interaction network derived from gene expression profile data
(GEO: GSE12452) of nasopharyngeal carcinoma (NPC) tissue speci-
mens along with an miRNA-sequencing dataset (GEO: GSE14738).
COL3A1, COL1A1, COL4A1, and COL5A2were found to be regulated
by several miR-29 family members, suggesting that miR-29 may be
related to the development of NPC by the regulation of these genes
involved in ECM-receptor interaction.186
Similarly, in a study aiming to explore the regulatory mechanism of
CRC and potential novel biomarkers for screening, COL1A1 was
predicted to be targeted by miR-29 from examining the protein-
protein interaction network (PPI) from microarray data (GEO:
GSE44861).187 In 2013, a study found that the reduction of
miR-29 expression led to increased cisplatin resistance of ovarian
cancer cells, partly through upregulating the expression of ECM
components such as COL1A1 in vitro and in vivo and also via
increasing the activation of ERK1/2 and inactivation of GSK3b.
Therefore, the downregulation of miR-29 in ovarian cancer cells
manipulates the surrounding ECM to enhance survival signal trans-
duction upon cisplatin treatment. Ectopic expression of miR-29
alone or in combination with cisplatin effectively reduced tumorige-
nicity of CP70 ovarian cancer cells in vivo, suggesting that miR-29
overexpression may have therapeutic implications as a potential
sensitizer to cisplatin treatment by remodeling the ECM.188 Further-
more, a recent study displayed the role of the miR-29 family in pre-
serving cardiac health in the regulation of age-dependent increases
of oxidative stress and cardiac fibrosis. It was found that the
miR-29 family is one of the most upregulated miRNAs during ag-
ing, and its increase induces the downregulation of known targets
such as collagens, DNMTs, and 50methylcytosine (5mC). In addi-
tion, under hypoxic conditions, miR-29a/-29b downregulation was
found to be responsible for collagen deposition and fibrosis. There-
fore, the miR-29 family upregulation may play a role as an endog-182 Molecular Therapy: Oncolytics Vol. 12 March 2019enous mechanism against cardiac fibrosis and hypertrophy in
age-dependent cardiac damage.189
Pancreatic cancer is notoriously known to be one of the most fibrotic
cancers, and its associated stroma has been shown to play an integral
role in tumor progression and resistance to therapy.190 Pancreatic
ductal adenocarcinoma (PDAC) is unique in that the degree of intra-
tumoral fibrosis is so extreme inmany cases that the bulk of the tumor
is made up of the stromal compartment.190 Hence, pancreatic cancer
frequently serves as a surrogate in studying cancer-stroma interac-
tions. In PDAC tumors, pancreatic stellate cells (PSCs) are mainly
responsible for the production of ECM proteins and the dense fibrotic
stroma surrounding the tumor bed. Cancer cells secrete a slew of
pro-inflammatory growth factors and cytokines, including TGF-b1,
which activate PSCs. In turn, activated PSCs and fibroblasts produce
pro-inflammatory growth factors and chemokines that act in an
autocrine fashion to maintain their sustained activity and produce
fibrotic stromal ECM proteins.191 In recent years, we found a signif-
icant downregulation of miR-29a and miR-29b in TGF-b1-activated
PSCs, fibroblasts, as well as cancer-associated fibroblasts (CAFs).45
Furthermore, we found that miR-29 was significantly downregulated
in PSCs of a KRAS mutant genetically engineered mouse model of
pancreatic cancer (KC) as well as in PDAC patient biopsies via
miRNA in situ hybridization.45 Restoration of miR-29a or -29b in
activated PSCs caused a drastic decrease in the expression of various
ECM proteins, and it reduced cancer colony growth in co-culture.45
Taken together, our studies indicate that miR-29 may have therapeu-
tic relevance beyond just the cancer cells themselves. Further studies
may reveal miR-29 to be a potent anti-tumorigenic agent in other
stromal cells as well.
miR-29 has also been observed to target genes outside of the ECM
network to provide protective effects against fibrosis. Arrestin beta 1
(ARRB1) is a member of the arrestin and beta-arrestin protein fam-
ily thought to participate in agonist-mediated desensitization of
G-protein-coupled receptors and cause dampening of cellular re-
sponses to stimuli, such as hormones, neurotransmitters, or sensory
signals. In a 2017 study, miR-29 along with miR-652 were indicated
as biomarkers in liver fibrosis. In a luciferase reporter-based target
validation assay, ARRB1 was identified as a target gene of these
two miRNAs in regulating the onset and progression of liver
fibrosis. Decreased expression of ARRB1 in addition to Th17, IL-
17A, and IL-22 was observed in miR-29a-transfected CD4+
T cells isolated from the spleen of normal mice. Moreover, miR-
29 overexpression led to decreased ALT, AST, Th17, and ARRB1
levels in vivo, suggesting the protective effects of miR-29 overexpres-
sion in liver fibrosis.192
The wider scope of these studies demonstrates anti-fibrotic activity of
miR-29 and its role in regulating a number of ECM proteins, and it
suggests an important role in the homeostasis of the ECM. A consid-
erable amount of experimental evidence has shown that restoring
downregulated miR-29 expression with synthetic miRNA mimics
may pose a suitable strategy to overcome fibrosis. Though, this
www.moleculartherapy.org
Reviewstrategy still needs to be validated in advanced preclinical studies and
in clinical settings.
Angiogenesis
The vascular system provides a vital channel to the delivery of nutri-
ents and oxygen, and it has been shown to be crucial for tumor
growth.193,194 Consistently, cancer cells exploit the process of angio-
genesis to generate new blood vessels to redirect nutrients and oxygen
for their growth.195 In addition to supplying provisions to cancer cell
growth, blood vessels also provide an effective conduit for metas-
tasis.195 Therefore, numerous efforts have been underway to target
angiogenesis in various cancers.196
miR-29 has been well implicated in the process of angiogenesis as an
anti-angiogenic agent by potently inhibiting VEGFA.197,198 VEGFA is
a functionally dominant member of the VEGF family of growth factor
proteins that is typically secreted and acts on endothelial cells to
promote their growth, migration, and angiogenic properties.199 As
expected, it has been reported that various cancers overexpress
VEGF,200 and a number of studies have shown all three miR-29 fam-
ily members to be potent tumor suppressors through directly target-
ing VEGFA.171,201–206
However, beyond the canonical downregulation of VEGF via 30 UTR
binding, a couple of other studies have indicated new mechanisms of
regulation involving miR-29 sponging and a role in cancer-stroma
cross-talk. An interesting report on osteosarcoma claimed a novel
mechanism by which the miR-29-binding site within the 30 UTR of
IGF1 functions as a competing endogenous RNA for miR-29.207 By
effectively sponging miR-29, authors showed an increase in VEGFA
mRNA expression.207 This study stands alone in this claim, but this
newly proposed mechanism of competitive binding warrants further
studies nonetheless.
More recently, miR-29 has been proposed to be involved in a para-
crine cross-talk mechanism between cancer-secreted IGF2 on
VEGF expression in CAFs.203 Initial findings indicated that there
was a concordant elevated expression of IGF2 in cancer cells with
an increase in VEGF expression in CAFs, which conferred an unfa-
vorable prognosis in esophageal squamous cell carcinoma.203 Utiliz-
ing predictive algorithms, miR-29c and miR-127 were identified to
have some of the highest predictive scores for VEGF 30 UTR-binding
sites, and they were also found to be some of the most significantly
downregulated miRNAs in IGF2-treated CAFs.203 Follow-up func-
tional studies with both miRNAs revealed that only the overexpres-
sion of miR-29c led to a significant and consistent downregulation
of VEGF in CAFs.203
Furthermore, miR-29 expression has even been shown to correlate
with levels of tumor vasculature in clinical samples. In a study look-
ing at the expression levels of various miRNAs in endometrial
patient biopsies, miR-29b was found to be significantly downregu-
lated in tumor samples compared to normal endometria and had
a significant inverse correlation with the degree of tumor vascularinvasion.208 In addition, low miR-29 expression levels conferred
poorer survival.208
Collectively, an insurmountable number of studies demonstrate
that miR-29 effectively targets VEGFA, which is an appealing thera-
peutic target in cancer. In fact, several clinical trials have been con-
ducted or have been ongoing in an attempt to target VEGFA in
various cancers (ClinicalTrials.gov: NCT01351415, NCT01863693,
and NCT01239732). However, anti-angiogenesis treatment alone
does not eliminate cancer completely and requires a combination
therapeutic approach.196 Perhaps, miR-29 may also serve as an alter-
native and effective means of targeting VEGFA in combination with
other therapies.
Immunomodulation
miR-29 has been shown to play a role in various immune-related
aspects, from adaptive and innate immune responses107 to viral path-
ogenesis.89,209 Although miR-29 has not been studied extensively in
cancer immunity, a few studies have started to reveal its role in the
context of cancer immunity.
B7-H3 is a potent immune checkpoint inhibitor that is known to
be overexpressed by cancer cells and causes T cell suppression.210 Un-
surprisingly, B7-H3 has become an appealing therapeutic target in
cancer.210 In fact, a monoclonal antibody targeting B7-H3 is already
undergoing clinical trials (ClinicalTrials.gov: NCT02475213). More-
over, a study investigating various solid tumors found all three
miR-29 family members to be significantly downregulated in multiple
cancers compared to normal tissues and inversely correlated with
B7-H6 expression.211 The B7-H6 miR-29-binding site was validated,
and overexpression of miR-29a led to a potent inhibition of B7-H6
expression.211 Although these findings convincingly demonstrate a
potential use of miR-29 as a therapeutic inhibitor of B7-H6, further
studies are needed to provide evidence of functional significance
in vivo.
Another interesting immune-related mechanism of miR-29 was
discovered in liver cancer, where miR-29a overexpression in HCC
cells downregulated cancer cell migration while simultaneously
increasing migration of CD8+ T lymphocytes in vivo.157 miR-29 over-
expression downregulated IGF-1R in HCC cells, which led to an
increased production of chemokine ligand 5 (CCL5).157 CCL5 is
important for chemotactic movement of CD8+ T lymphocytes,212
and this was of particular significance as patients with high CCL5 ex-
hibited better survival rates due to increased immune cell infiltration
into the tumor.157 Albeit the mechanism was through indirect effects,
these results still provide additional evidence of miR-29’s immuno-
modulatory function in cancer.
Beyond miR-29’s intrinsic function within cancer cells, miR-29 has
also been shown to elicit an inflammatory response extrinsically. A
subset of immune cells has been known to detect exogenous RNA
through Toll-like receptors (TLRs) and trigger an inflammatory im-
mune response.213,214 As miRNAs had been reported to be releasedMolecular Therapy: Oncolytics Vol. 12 March 2019 183
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secreted miRNAs interact with TLRs in the context of cancer.215
Indeed, miR-29a was shown to be secreted and co-immunoprecipi-
tated with TLR7.215 Furthermore, miR-29a was found to co-localize
with macrophage TLR7 and TLR8 in vivo.215 Ultimately, miR-29
binding to TLRs led to nuclear factor kB (NF-kB) activation and sub-
sequent cytokine production that enhanced the metastatic potential
of cancer.157 This proved to be a novel means by which miRNAs
can function in an extrinsic manner beyond their canonical target
mRNA 30 UTR-binding mechanisms.
Only a handful of reports have demonstrated miR-29’s role in cancer
immunomodulation, and, among these few studies, all were within
the context of cancer cells. It has yet to be determined whether
miR-29 plays an intrinsic role within immune cells themselves in rela-
tion to cancer pathogenesis. Certainly, miR-29’s role in immune cells
outside of the tumor setting has been studied. For example, systematic
screening of >100 individual miRNAs in helper T cells revealed miR-
29 as a critical regulator of the IFN-g pathway through the direct tar-
geting of two critical transcription factors, T-bet and Eomes.216 T cells
are known to be involved in the cancer immune response,217 and,
therefore, it is not hard to imagine that miR-29 could have a function-
ally important role in cancer immunity as well. The investigation of
miR-29 expression status and function in the context of intratumoral
immune cells is of particular interest and remains an open area of
research.
Clinical Findings and Prognostic Implications
The majority of accounts have reported miR-29 to have a tumor sup-
pressor function in various cancer types. However, compared to the
number of mechanistic studies of miR-29 in cancer, there are notice-
ably fewer studies interrogating the clinical ramifications of miR-29
expression for patient overall survival and outcomes. Herein, we
touch on the current state of miR-29 as a potential prognostic marker.
In lung cancer, a study profiling the miRNA expression levels in tu-
mor biopsies foundmiR-29b to be one of the most significantly down-
regulated miRNAs.218 Consistently, another study sought to define
molecular features that distinguish lung squamous cell carcinoma
versus adenocarcinoma, and the researchers found that all three
miR-29 family members were more heavily downregulated in squa-
mous cell carcinoma, with miR-29a as one of the most prominently
downregulated miRNAs.219 Even though miR-29 was significantly
downregulated in lung tumors, these studies highlighted various
other miRNAs as having a more prominent effect in predicting over-
all survival.218,219 However, a more recent report specifically looking
at the impact of miR-29 expression level on overall survival and
relapse-free survival in lung cancer patients found that patients
with tumors expressing high miR-29 led to significantly better sur-
vival outcomes.220 Oftentimes, all three miR-29 family members
were found to negatively correlate with prognostically unfavorable
pulmonary neuroendocrine tumor grades. In contrast to miR-29
expression levels in tumors, two independent groups profiled circu-
lating miRNA levels, and they found that higher levels of miR-29 in184 Molecular Therapy: Oncolytics Vol. 12 March 2019plasma conferred lower survival rates.221,222 Although tumor expres-
sion and liquid biopsies are not one in the same, these results are still
confounding.
These incongruent results are found in various lymphoma-related
studies as well. In a single study, miR-29c was found to be upregulated
in AML patients and was associated with a higher risk of relapse.223 In
stark contrast, miR-29a was found to be significantly decreased in the
bone marrow samples of 106 AML patients.224 Furthermore, high
miR-29a expression was associated with more favorable prognosis,
increased survival, and relapse-free survival.224 Concordant with
these results, another study found bothmiR-29a andmiR-29b expres-
sion levels to be significantly downregulated in myeloid leukemia and
inversely correlated with anti-apoptotic gene BCL2 andMCL1 expres-
sion levels.225 The authors noted that lower levels of BCL2 andMCL1
had been reported to confer better overall survival in myeloid leuke-
mia patients. However, the study did not demonstrate that miR-29
expression correlated with survival within their patient samples.225
There are limited reported studies regarding the prognostic value of
miR-29 in other cancer types. Nevertheless, many of these studies
seem to consistently indicate that high miR-29 expression leads to
increased survival. In the case of mantle cell lymphoma, patients
with significantly decreased miR-29 levels had shorter survival and
had an inverse correlation with CDK6.105 Similar findings were
reported in gastric cancer,226 melanoma,227 and serum miR-29 in
high-grade glioma,228 where increased miR-29 indicated better
survival.
From the existing evidence, the prognostic value of miR-29 expres-
sion is not clear and further studies are needed. Yet, most of these
biomarker studies simply dichotomize patient cohorts based on
high versus low miR-29 expression. Perhaps, further studies with a
higher degree of scrutiny in patient stratification will better clarify
and rectify these mixed results.
Discussion
Since the discovery of the first miRNA, the area of miRNA research
has rapidly expanded and moved beyond basic biology into therapeu-
tic use. Just within the past two decades, >2,000 patent documents
related to miRNAs have been published.229 Nonetheless, the develop-
ment of miRNA therapeutics lags behind many other forms of treat-
ment, including RNAi-based drugs.230 Furthermore, recent setbacks
were made when the first miRNA replacement therapy clinical trial,
testing the therapeutic effect of miR-34 (MRX34) in cancer, was
halted at phase I due to immune-related side effects.231 However,
some arguments have been made that the adverse events of the
MRX34 clinical trials were not due to miR-34 itself, but rather caused
by the method of delivery (e.g., liposomes) or immunostimulation
induced by double-stranded RNA.231,232
Nevertheless, the promise of miRNA-based therapies in their ability
to simultaneously target multiple disease-related pathways has re-
mained appealing, as indicated by numerous therapeutic products
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companies.230 In fact, the miR-29 mimic MRG-201 is currently being
tested in phase I clinical trials via intradermal injection (Clinical-
Trials.gov: NCT02603224). Recently, a major milestone has been
accomplished in the area of small RNA therapeutics, with the advent
of the first FDA-approved siRNA treatment for a rare neurological
disease, hereditary transthyretin-mediated amyloidosis (hATTR).
The siRNA, patisiran, functions by inhibiting abnormal transthyretin
(TTR) to reduce amyloid deposits and significantly improves
symptoms associated with hATTR, including reflexes and motor
strength.233 The delivery method in the clinical study also utilized
a lipid nanoparticle to package and deliver the siRNAs, but it is
important to note that there were complications associated with
patisiran infusion.233 However, with the administration of anti-in-
flammatory drugs and antihistamines alleviated these issues.233 As
new and improved modes of gene delivery are developed and
tested,234–236 it may be just a matter of time before the therapeutic de-
livery of miR-29 will be tested in cancer.
Although miR-29 may seem to show a high degree of promise as
a potent tumor suppressor, the minority of studies reporting miR-
29 as an oncogene are still grounds for circumspection and must
be strongly taken into consideration (Figure 2B). The opposing
effects of miR-29 reported even within the same cancer types, such
as breast cancer174,183,237,238 and pancreatic cancer,158,163,165,166,172
are confounding.
In breast cancer, two studies took a systematic approach of assessing
miR-29 status in breast cancer, revealing similar results of miR-29 as a
tumor suppressor miRNA.174,183 While Zhu and colleagues183 con-
ducted a network analysis of gene co-expressions in hundreds of
clinical breast cancer samples, Duhachek-Muggy and Zolkiewska237
profiled a panel of 50 breast cancer cell lines. Although overlapping
breast cancer cell lines (BT549 and MDA-MB-231) were utilized in
validating downstream mechanisms in both studies, only Zhu
et al.183 showed functional impact of miR-29b and -29c in reducing
colony formation. In two separate studies investigating the role of
miR-29 in the context of breast cancer cell response to progesterone
receptor activation, Cochrane et al.174 postulated that miR-29a and
miR-29b function as tumor promoters by inhibiting ATP1B1 expres-
sion. In direct contrast, Cittelly et al.238 demonstrated that miR-29 in-
hibition in T47D and BT474 cells using antagomirs leads to increased
growth in 3D colony formation assays. Further in vivo validation in an
orthotopic mouse model demonstrated mir-29 inhibition leads to
greater tumor growth and metastases. Although Cittelly and col-
leagues238 utilized the same breast cancer cell line, T47D, they found
contradictory results. However, Cochrane et al.174 only conducted an
in vitro viability assay in the T47D cell line, and they did not verify the
impact of miR-29 in vivo.
In pancreatic cancer, four studies found that miR-29 exhibited a tu-
mor-suppressive function,158,163,165,166 as opposed to a single study
that showed entirely opposite effects.172 Four studies functionally
verified the tumor-suppressive properties of miR-29 by transfectingmiR-29 mimics in pancreatic cancer cells and subjecting them to
various in vitro assays to assess migration/invasion, anchorage-inde-
pendent growth, and proliferation.158,165,166 Two studies went on to
test the functional effect of miR-29 in vivo, and they consistently
found that miR-29 suppressed tumor growth.158,163 In direct contrast
to these studies, Sun and colleagues172 found that miR-29a functions
as a tumor promoter in various in vitro assays as well as in vivo.
Further confusion arises when multiple mechanisms are proposed
to explain the anti-tumor effects of miR-29 within the same cancer.
For example, miR-29 was shown to have anti-metastatic potential
in pancreatic cancer, yet all three reports offered alternative hypoth-
eses for which miR-29 target downregulation leads to reduced migra-
tion/invasion (MMP2, MUC1, ITGB1).158,163,166
Some of the discrepancies of these studies can be explained by subtle
differences in methodologies and the utilization of different cell lines.
For example, although Cochrane et al.174 and Cittelly et al.238 found
opposite results for miR-29 in the same cell line, T47D, Cittelly
tested the impact of miR-29 in a particular CD44+ cancer stem
cell subpopulation.238 However, there are examples in which using
the exact same methodology and cell lines yielded contradictory re-
sults. Sun et al.172 found miR-29a to be increased in Panc-1 and
BxPC-3 cell lines compared to a normal pancreatic epithelial line.
In direct contrast, Tréhoux et al.166 and Kwon et al.165 consistently
found its significant downregulation in various pancreatic cancer
cell lines, including MIA PaCa-2, Panc-1, and BxPC-3, compared
to normal pancreatic epithelial cell lines. Further discrepancies arise
whereby Sun et al.172 overexpressed miR-29a mimic similar to both
Tréhoux et al.166 and Kwon et al.,165 only to find the exact opposite
results of increased cell proliferation and migration. A potential
explanation for these confounding results could be explained by
recent reports demonstrating heterogeneity between the same cell
line from different labs.239 27 strains of the same well-utilized cell
line MCF7 demonstrated immense genetic diversity and a large vari-
ability in drug response.239 By speculation, the opposing results of
these studies could be explained by the diversity that resides within
the same cell lines. Nevertheless, these incongruities demand the
need for further studies and greater meticulous measures in vali-
dating cell lines and reagents to better understand these contradic-
tory results.
Genomic heterogeneity is a well-known feature of cancer exists be-
tween tumors of different patients and is even evident within the
same tumor.240 In recent years, there has been a paradigm shift
toward classifying cancers based on genetic alterations rather than
in the context of anatomical location. In fact, Pembrolizumab was
the first recently FDA-approved cancer therapy on the basis of the
patients’ tumor gene expression profile instead of the cancer’s origi-
nating tissue type. As miRNAs function in a context-dependent
manner,241–244 the discrepancies of miR-29 function and alternative
mechanisms of action may be due to a lack of contextualizing
miR-29 against specific genetic backgrounds. This is particularly rele-
vant given that several different mechanisms of regulating miR-29
expression have been reported. Common mechanisms of miR-29Molecular Therapy: Oncolytics Vol. 12 March 2019 185
Figure 3. miR-29 Targets in the Mechanisms of Cancer
Schematic illustration depicts the reported targets of miR-29 involved in epigenetics, proteostasis, metabolism, proliferation, apoptosis, metastasis, fibrosis, angiogenesis,
and immunomodulation.
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suppressing miR-29 expression in various cancers.125,245,246 However,
a few context-specific dysregulations of miR-29 expression have been
demonstrated as well.
Given the anti-inflammatory role of miR-29 in fibrosis, it is not
surprising that TGF-b1-SMAD signaling has been shown to directly
downregulate miR-29 expression.7–12 Consistently, restoration of
miR-29 in activated pancreatic fibroblasts has been shown to reduce
cancer cell proliferation in co-culture systems, and miR-29 downre-
gulation in these fibroblasts was found to be SMAD3 dependent.45
These findings coincide with similar effects reported in ovarian can-
cer, where TGF-b1 has been shown to elicit pro-tumorigenic function
by simultaneously downregulating miR-29.247 However, the majority
of reports demonstrating TGF-b1-SMAD3/4-mediated miR-29 sup-
pression have been in the context of fibroblasts and fibrosis. Thus,
this mechanism of miR-29 dysregulation may be a more fibroblast-
specific phenomenon.186 Molecular Therapy: Oncolytics Vol. 12 March 2019A notable example of miR-29 dysregulation involves NF-kB and YY1.
Both NF-kB and YY1 have been shown to be vital in the process
of regulating myocyte differentiation.248,249 In rhabdomyosarcoma,
miR-29 has been found to be a tumor suppressor, where the molecule
downregulates several cell cycle regulatory genes.128 Unsurprisingly, a
rhabdomyosarcoma-specific mechanism of miR-29 dysregulation
was found to be mediated by an NF-kB-YY1-miR-29-signaling axis,
whereby YY1, under the regulation of NF-kB, directly binds to the
miR-29 promoter site, and it modulates its expression epigenetically
via a negative feedback loop mechanism and by closing the accessi-
bility of chromatin modulation at the miR-29 promoter site.250
Another context-specific example of miR-29 dysregulation involves
the transcription factor GATA3. Specifically, GATA3 has been shown
to be a tumor suppressor in breast cancer by maintaining luminal cell
differentiation and inhibiting metastasis.251,252 Accordingly, the loss
of GATA3 has been shown to be associated with poor prognosis,
and it was found to be mutated in several cases of breast cancer.253,254
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tumor suppressor, miR-29 was found to be a critical downstream
target of GATA3.171 Specifically, miR-29b was found to be the most
differentially upregulated miRNA by GATA3, where GATA3 directly
binds to the promoter of miR-29.171 Finally, miR-29 was found to be a
dominant effector of GATA3, where the inhibition of miR-29 was
found to be sufficient for ablating the GATA3 tumor suppressor
function.171
Most of the current miR-29-related literature in cancer frequently
generalizes the function of miR-29 within the framework of organ-
based stratification, without acknowledging the genetic background
of the cells and biopsies. This may be due to utilizing a traditional,
reductionist approach in biology. Factoring in many genetic variables
is a daunting if not impossible task. However, recent advancements in
systems biology and high-throughput technologies, such as proteoge-
nomics, next-generation sequencing, single-cell sequencing, and
functional genomics, have allowed the field to gain a more refined
insight into global gene regulation, as well as having provided a
more systematic approach to testing the function of genes on a large
scale. Furthermore, the accumulation of large genomic databases (e.g.,
Human Cell Atlas, TCGA, The Human Protein Atlas, Project Achil-
les, DepMap, PRISM, and Cancer Cell Line Encyclopedia) has al-
lowed for a greater degree of resolution in studying the heterogeneity
associated with cancer.
Indeed, some systematic approaches have been conducted formiR-29.
For example, miRNA expression across 10 cancer types was analyzed
in TCGA database to determine commonalities in miRNA-target
networks.64 Notably, “miR-29a was generally downregulated.in
tumors of most cancer types as compared with representative normal
samples.”64 Still, other analyses utilizing comprehensive, unbiased
approaches find similarly consistent results of miR-29 as a tumor sup-
pressor.255,256 With time, further methodical studies employing these
techniques and utilizing big data may provide a more auspicious
approach to better understanding miR-29’s function in the context
of cancer, and they may clarify its disputed role as tumor suppressor
versus tumor promoter.
The multifaceted function of miR-29 casts doubts in claiming it as a
panacea for cancer. It seems that miR-29’s dichotomous role as a
tumor suppressor versus oncogene may be context dependent. How-
ever, at the current moment, miR-29 has been predominantly shown
to function as a tumor suppressor in themajority of publications, with
>85% of all miR-29-cancer-related studies (Figure 2B) demonstrating
miR-29 inhibiting various cancer-related targets (Figure 3). Future
studies are of interest to see if investigating the function of miR-29
in a more comprehensive and systematic manner will resolve these
disputes and elucidate a more refined perspective on miR-29’s role
in cancer.
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